2025-06-01 2026-05-31 false No description of principal activity Acting Office - Tax and Accounts 1.0 12598519 bus:AbridgedAccounts 2025-06-01 2026-05-31 12598519 bus:SmallEntities 2025-06-01 2026-05-31 12598519 bus:AuditExempt-NoAccountantsReport 2025-06-01 2026-05-31 12598519 bus:SmallCompaniesRegimeForAccounts 2025-06-01 2026-05-31 12598519 bus:PrivateLimitedCompanyLtd 2025-06-01 2026-05-31 12598519 2025-06-01 2026-05-31 12598519 2026-05-31 12598519 bus:RegisteredOffice 2025-06-01 2026-05-31 12598519 core:WithinOneYear 2026-05-31 12598519 core:AfterOneYear 2026-05-31 12598519 2024-06-01 12598519 bus:Director1 2025-06-01 2026-05-31 12598519 bus:Director1 2026-05-31 12598519 bus:Director1 2024-06-01 2025-05-31 12598519 bus:CompanySecretary1 2025-06-01 2026-05-31 12598519 bus:LeadAgentIfApplicable 2025-06-01 2026-05-31 12598519 2024-06-01 2025-05-31 12598519 2025-05-31 12598519 core:WithinOneYear 2025-05-31 12598519 core:AfterOneYear 2025-05-31 12598519 bus:EntityAccountantsOrAuditors 2024-06-01 2025-05-31 12598519 core:OtherResidualIntangibleAssets 2025-06-01 2026-05-31 12598519 core:OtherResidualIntangibleAssets 2026-05-31 12598519 core:OtherResidualIntangibleAssets 2025-05-31 12598519 core:CostValuation core:Non-currentFinancialInstruments 2026-05-31 12598519 core:CostValuation core:Non-currentFinancialInstruments 2025-05-31 12598519 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2026-05-31 12598519 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2026-05-31 12598519 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2026-05-31 12598519 core:ShareProfitOrLossIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2026-05-31 12598519 core:ProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2026-05-31 12598519 core:ImpairmentReversalProvisionsForImpairmentInvestments core:Non-currentFinancialInstruments 2026-05-31 12598519 core:ForeignExchangeDifferencesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2026-05-31 12598519 core:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2026-05-31 12598519 core:TransfersBetweenInvestmentClassesIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2026-05-31 12598519 core:Non-currentFinancialInstruments 2026-05-31 12598519 core:Non-currentFinancialInstruments 2025-05-31 12598519 core:ShareCapital 2026-05-31 12598519 core:ShareCapital 2025-05-31 12598519 core:RevaluationReserve 2026-05-31 12598519 core:RevaluationReserve 2025-05-31 12598519 core:RetainedEarningsAccumulatedLosses 2026-05-31 12598519 core:RetainedEarningsAccumulatedLosses 2025-05-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 12598519
England and Wales

 

 

 


Abridged Accounts

for the year ended 31 May 2026

for

KADEN BIOTECH LIMITED

 
 
Notes
 
2026
£
  2025
£
Fixed assets
Intangible fixed assets 32,620    32,620 
Investments 517,470    498,970 
550,090    531,590 
Current assets
Debtors -    10,000 
Cash at bank and in hand 4,846    14,039 
4,846    24,039 
Creditors: amount falling due within one year (372,897)   (367,222)
Net current assets/(liabilities) (368,051)   (343,183)
 
Total assets less current liabilities 182,039    188,407 
Net assets/(liabilities) 182,039    188,407 
 

Capital and reserves
Called up share capital 300    300 
Reserves 127,604    127,604 
Profit and loss account 54,135    60,503 
Shareholders fund 182,039    188,407 
 
For the year ended 31 May 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's Responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime of Part 15 of the Companies Act 2006 and in accordance with the provisions of FRS 102 Section 1A - small entities.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).
Signed on behalf of the board of directors:


---------------------------------------------
Jason Edward Borrows
Director

Date approved: 18 September 2026
1
Statutory Information
Kaden Biotech Limited is a private limited company, limited by shares, domiciled in England and Wales, registration number 12598519, registration address 31a Thayer Street, London, W1U 2QS, England.

The presentation currency is £ sterling.
1.

Accounting Policies

Basis of accounting
The financial statements have been prepared under the historical cost convention and in accordance with Section 1A of FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.
Intangible assets
Intangible assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight-line basis over their estimated useful economic lives. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable.
Fixed asset investments
Fixed asset investments are stated at cost less provision for any permanent diminution in value.
Cash and cash equivalents
Cash and cash equivalents are highly liquid investments and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.
Trade and other creditors
Short-term creditors are measured at the transaction price. The other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of The Company.
2.

Average number of employees

Average number of employees during the year was 1 (2025: 1).
2